BioXcel Therapeutics (BTAI) Stock Forecast, Price & News

BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

Is BioXcel Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioXcel Therapeutics stock.
View analyst ratings for BioXcel Therapeutics or view top-rated stocks.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for BioXcel Therapeutics.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its earnings results on Monday, May, 9th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.21) by $0.09. During the same period in the previous year, the business posted ($1.08) earnings per share.
View BioXcel Therapeutics' earnings history.

What price target have analysts set for BTAI?

6 equities research analysts have issued twelve-month price objectives for BioXcel Therapeutics' shares. Their forecasts range from $24.00 to $110.00. On average, they anticipate BioXcel Therapeutics' share price to reach $65.00 in the next year. This suggests a possible upside of 430.6% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics or view top-rated stocks among Wall Street analysts.

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:

• Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, & Director (Age 61, Pay $1.41M)
• Dr. Frank D. Yocca Ph.D., Sr. VP & Chief Scientific Officer (Age 66, Pay $452.58k)
• Mr. Javier Rodriguez, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 50, Pay $470.53k)
• Dr. Krishnan Nandabalan Ph.D., Chief Digital Officer ?& Director (Age 59, Pay $150k)
• Mr. Richard I. Steinhart MBA, Sr. VP & CFO (Age 65)
• Ms. Mary Coleman, VP of Investment Relations
• Dr. Iris Francesconi Ph.D., Sr. VP of Marketing, Market Research & Commercial Assessments
• Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 53)
• Dr. Cedric Burg, VP and Head of Global Clinical Operations & Project Management
• Mr. Matthew Wiley, Sr. VP & Chief Commercial Officer (Age 49)

Who are some of BioXcel Therapeutics' key competitors?

Some companies that are related to BioXcel Therapeutics include Xencor (XNCR), Sierra Oncology (SRRA), Prothena (PRTA), Cryoport (CYRX), IVERIC bio (ISEE), 23andMe (ME), Celularity (CELU), BELLUS Health (BLUSF), Madrigal Pharmaceuticals (MDGL), Zentalis Pharmaceuticals (ZNTL), MannKind (MNKD), Prometheus Biosciences (RXDX), NGM Biopharmaceuticals (NGM), Agios Pharmaceuticals (AGIO) and Arcutis Biotherapeutics (ARQT).
View all of BTAI's competitors.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (5.10%), State Street Corp (5.01%), BlackRock Inc. (4.58%), Vanguard Group Inc. (3.79%), Massachusetts Financial Services Co. MA (1.52%) and Northern Trust Corp (0.70%). Company insiders that own BioXcel Therapeutics stock include Bioxcel Llc, Frank Yocca, Vimal Mehta and Vincent O'neill.
View institutional ownership trends for BioXcel Therapeutics.

Which major investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., UBS Group AG, BlackRock Inc., HITE Hedge Asset Management LLC, Metropolitan Life Insurance Co NY, California State Teachers Retirement System, DAVENPORT & Co LLC, and Simplex Trading LLC. Company insiders that have sold BioXcel Therapeutics company stock in the last year include Bioxcel Llc, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics or view top insider-selling stocks.

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, State Street Corp, Jane Street Group LLC, Apis Capital Advisors LLC, Vanguard Group Inc., Graham Capital Management L.P., PDT Partners LLC, and Worth Venture Partners LLC.
View insider buying and selling activity for BioXcel Therapeutics or or view top insider-buying stocks.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $12.25.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics has a market capitalization of $342.82 million. The company earns $-106.93 million in net income (profit) each year or ($4.12) on an earnings per share basis.

How many employees does BioXcel Therapeutics have?

BioXcel Therapeutics employs 89 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at (475) 238-6837 or via email at [email protected].